Roivant Sciences Ltd. (ROIV) Misses Q1 EPS by 10c

Roivant Sciences Ltd. (NASDAQ: ROIV) reported Q1 EPS of ($0.38), $0.10 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $21.62 million versus the consensus estimate of $24.77 million.

For earnings history and earnings-related data on Roivant Sciences Ltd. (ROIV) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
• Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus